Project Grant R41AI124734

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Cellergy Pharma Inc. to develop a bispecific antibody therapy that can efficiently and specifically eliminate IgE-producing B cells without significant side effects. The goal is to achieve complete and durable suppression of allergic symptoms for severe allergic diseases affecting millions of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $320,863 to Aaiit LLC (Inflammation Immuno Therapy) to develop a bifunctional IgE antagonist and dissociator (ANDI) drug to treat severe allergic asthma. The ANDI drug aims to directly access and dissociate IgE bound to mast cell receptors, in contrast to the first-generation Xolair drug which only...

This federal Project Grant award, valued at $612,917 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the role of the inhibitory receptor Siglec-9 in modulating mast cell function and its potential for therapeutic targeting in mast cell-associated disorders. The awardee, Seattle Children's Hospital (doing business as Seattle Children's Research Institute), will...

This federal Project Grant award of $586,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate the generation and regulation of TFH13 cells that drive pathogenic IgE in allergic conditions. The overarching goal is to elucidate the pathways leading to TFH13 cell differentiation, which play a critical...

This Project Grant award of $440,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to develop a new deep learning approach to investigate the molecular basis of inhalation allergens. The key objectives are to: 1) Optimize a deep learning model called SDAP_AI to predict protein allergenicity using sequence data from the Structural Database of Allergenic Proteins (SDAP 2.0),...

This federal Project Grant award of $202,314 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a 5-year research program to investigate the mechanisms of increased intestinal epithelial cell (IEC) barrier permeability in peanut allergy. The research will utilize a novel mouse model and primary human intestinal cell cultures to examine how alterations in the gut microbiome and IEC...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...

This Project Grant award of $470,553 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Emory University aims to elucidate the genetic factors regulating the immune response to factor VIII (FVIII) in patients with hemophilia A. The research will use a genetically diverse mouse model to identify key genetic traits that influence the development of anti-FVIII antibodies, which can render FVIII replacement therapy...

This federal Project Grant award of $612,328 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to enhance the understanding of mast cell lineage commitment and function. The research aims to determine how the transcription factor MITF maintains mast cell-specific gene expression and suppresses basophil-specific gene expression, as well as evaluate the functional deficiencies of mast...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $262,098 to the University of Wisconsin - Madison to develop and characterize human induced pluripotent stem cell (iPSC)-derived neutrophil therapies against pathogenic Aspergillus fungi. The key objectives are to assess the ability of iPSC-derived neutrophils to inhibit the growth of the two most common causative agents...